Interview with John Montgomery , CEO, Alphapharm
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
Address: Level 1, 181 Bay Street, BRIGHTON
VIC 3186, Australia
Tel: +613 9595 3556
Web: http://www.drreddys.com/australia/
Dr. Reddy’s Australia was one of the key sponsors at the annual New South Wales (NSW) Chemists Golf Day. The event saw pharmacists and industry professionals join hands together to help raise funds for building a burn unit at Concord Hospital in NSW.
The event was held at Concord Golf Club, one of the Sydney’s most prestigious golf clubs. A total of 108 people participated in the event. The event raised over $16,000 bringing the total money raised to $96,000 since 2006. The money was donated to the Burns Unit at Concord Hospital which helped fund 12 out of the total 18 rooms in the unit.
Our portfolio of products for the Australian market focuses on various therapeutic areas like Gastro-Intestinal, Anti-Infective, Urology, Cardiovascular diseases, Central Nervous System and Anti-Epileptic.
Alphapharm recently celebrated its 25th anniversary. In light of this significant milestone, would you give us a brief introduction to the company? Alphapharm started in 1982 in Brisbane with a…
What impact have the PBS reforms had on sanofi-aventis in Australia? Sanofi-aventis has one of the largest portfolios of medicines in Australia, with over 240 products in the key areas…
Would you please introduce Pretium’s specific service offerings, and the focus within these? Pretium offers a comprehensive range of integrated services across our 4 lines of business – Market Intelligence,…
What are some of the challenges facing pharmaceutical companies in Australia today? There are four major challenges within the Australian pharmaceutical industry at the moment. The increasing complexity of getting…
As ASMI President and Managing Director of Galderma, would you please give us a brief overview of the Australian OTC market and Galderma’s role therein? Galderma is a leading player…
What impact have the PBS reforms had on Amgen in Australia? From a company perspective, biotechnology companies exist in a competitive space. They have predominantly niche medicines with significant competitive…
2006 marked a major milestone, with the Pharmaceutical Industry Action Agenda transformed from a Government-industry initiative into an industry-driven agenda, and the resulting creation of the Pharmaceutical Industry Council (PIC).…
As a biopharmaceutical company, how have the PBS reforms affected Celgene? Celgene looks at the PBS reforms more positively than negatively. As a company with a smaller product portfolio of…
One of the hot topics in the industry is the impact of PBS reforms. Can you speak to recent influence of PBS reforms affecting Novotech’s services in Australia? In our…
How will the PBS reforms affect Solvay? The easy answer is: heavily. Fortunately, Solvay’s leading product which is still under patent will not be subject to the full August 1…
What impact will the recent PBS reforms have on Stiefel’s operations in Australia? Stiefel has no products on the PBS at the moment, and although that doesn’t preclude the company…
Many MNCs are having pipeline concerns in the “new era” of post-blockbuster drug development. How is Bayer positioned in this respect? Bayer Schering Pharma has one of the richest pipelines…
See our Cookie Privacy Policy Here
